Par Pharmaceutical, Inc.

ARS Pharmaceuticals Q4 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for Type I allergic reactions including anaphylaxis, while emphasizing that growth in the category has be

Source: MarketBeat Mar 9, 2026

How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe

ARS Pharmaceuticals recently reported that the European Medicines Agency’s CHMP issued a positive opinion to expand EURneffy’s marketing authorization to include a 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children weighing 15 kg to under 30 kg across the EU, Iceland, Liechtenstein and Norway. This move effectively extends EURneffy’s needle-free anaphylaxis treatment franchise to younger pediatric patients in Europe, adding to existing approvals and...

Source: Simply Wall St. Feb 3, 2026

Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump

ARS Pharmaceuticals (SPRY) has attracted fresh attention after a strong single-day move, with the stock up 19.3% and solid gains over the past week, month, and past 3 months. See our latest analysis for ARS Pharmaceuticals. That 19.3% single day gain sits within a broader upswing, with the share price return over the past month and quarter both in positive territory and the 3 year total shareholder return of 75.3% pointing to ongoing interest in the company. Overall, recent share price...

Source: Simply Wall St. Jan 11, 2026

ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2, Roth MKM reiterated its Buy rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) with a price target of $30 on the stock. In other news, on December 29, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) reported that China’s

Source: Insider Monkey Jan 9, 2026

ARS Pharmaceuticals announces NMPA approval for neffy 2 mg

ARS Pharmaceuticals (SPRY) announced that the National Medical Products Administration in China has granted approval for neffy 2 mg for the emergency treatment of Type 1 allergic reactions in adults and children who weigh 30 kg or more. ARS Pharma and Pediatrix Therapeutics anticipate filing for approval of neffy 1 mg dose for children greater than 15 kg and less than 30 kg in the coming months. ARS Pharma entered into an exclusive licensing agreement with Pediatrix Therapeutics in 2021, providi

Source: TipRanks Dec 30, 2025

ARS Pharmaceuticals Wins China Approval for First Community-Use Epinephrine for Allergic Reactions

ARS Pharmaceuticals (SPRY) said China's drug regulator has approved its epinephrine nasal spray neff

Source: MT Newswires Dec 29, 2025